Now showing items 2479-2498 of 4635

    • Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. 

      Bahig, H; Yuan, Y; Mohamed, ASR; Brock, KK; Ng, SP; Wang, J; Ding, Y; Hutcheson, K; McCulloch, M; Balter, PA; Lai, SY; Al-Mamgani, A; Sonke, J-J; van der Heide, UA; Nutting, C; Li, XA; Robbins, J; Awan, M; Karam, I; Newbold, K; Harrington, K; Oelfke, U; Bhide, S; Philippens, MEP; Terhaard, CHJ; McPartlin, AJ; Blanchard, P; Garden, AS; Rosenthal, DI; Gunn, GB; Phan, J; Cazoulat, G; Aristophanous, M; McSpadden, KK; Garcia, JA; van den Berg, CAT; Raaijmakers, CPJ; Kerkmeijer, L; Doornaert, P; Blinde, S; Frank, SJ; Fuller, CD (2018-11)
      Background Current standard radiotherapy for oropharynx cancer (OPC) is associated with high rates of severe toxicities, shown to adversely impact patients' quality of life. Given excellent outcomes of human papilloma virus ...
    • Magnitude of observer error using cone beam CT for prostate interfraction motion estimation: effect of reducing scan length or increasing exposure. 

      McNair, HA; Harris, EJ; Hansen, VN; Thomas, K; South, C; Hafeez, S; Huddart, R; Dearnaley, DP (2015-10)
      Objective Cone beam CT (CBCT) enables soft-tissue registration to planning CT for position verification in radiotherapy. The aim of this study was to determine the interobserver error (IOE) in prostate position verification ...
    • Major Amputations for Extremity Soft-Tissue Sarcoma. 

      Smith, HG; Thomas, JM; Smith, MJF; Hayes, AJ; Strauss, DC (2018-02)
      Introduction With modern techniques facilitating limb conservation, amputation for extremity soft-tissue sarcoma (ESTS) is now rare. We sought to determine the indications and outcomes following major amputation for ESTS ...
    • Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer. 

      Gao, Q; López-Knowles, E; U Cheang, MC; Morden, J; Ribas, R; Sidhu, K; Evans, D; Martins, V; Dodson, A; Skene, A; Holcombe, C; Mallon, E; Evans, A; Bliss, JM; Robertson, J; Smith, I; Martin, L-A; Dowsett, M; POETIC Trial Management Group and Trialists (2018-04)
      To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery ...
    • Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. 

      Silvestri, V; Barrowdale, D; Mulligan, AM; Neuhausen, SL; Fox, S; Karlan, BY; Mitchell, G; James, P; Thull, DL; Zorn, KK; Carter, NJ; Nathanson, KL; Domchek, SM; Rebbeck, TR; Ramus, SJ; Nussbaum, RL; Olopade, OI; Rantala, J; Yoon, S-Y; Caligo, MA; Spugnesi, L; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Toland, AE; Senter, L; Andrulis, IL; Glendon, G; Hulick, PJ; Imyanitov, EN; Greene, MH; Mai, PL; Singer, CF; Rappaport-Fuerhauser, C; Kramer, G; Vijai, J; Offit, K; Robson, M; Lincoln, A; Jacobs, L; Machackova, E; Foretova, L; Navratilova, M; Vasickova, P; Couch, FJ; Hallberg, E; Ruddy, KJ; Sharma, P; Kim, S-W; kConFab Investigators; Teixeira, MR; Pinto, P; Montagna, M; Matricardi, L; Arason, A; Johannsson, OT; Barkardottir, RB; Jakubowska, A; Lubinski, J; Izquierdo, A; Pujana, MA; Balmaña, J; Diez, O; Ivady, G; Papp, J; Olah, E; Kwong, A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Nevanlinna, H; Aittomäki, K; Perez Segura, P; Caldes, T; Van Maerken, T; Poppe, B; Claes, KBM; Isaacs, C; Elan, C; Lasset, C; Stoppa-Lyonnet, D; Barjhoux, L; Belotti, M; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Hahnen, E; Kast, K; Arnold, N; Varon-Mateeva, R; Wand, D; Godwin, AK; Evans, DG; Frost, D; Perkins, J; Adlard, J; Izatt, L; Platte, R; Eeles, R; Ellis, S; EMBRACE; Hamann, U; Garber, J; Fostira, F; Fountzilas, G; Pasini, B; Giannini, G; Rizzolo, P; Russo, A; Cortesi, L; Papi, L; Varesco, L; Palli, D; Zanna, I; Savarese, A; Radice, P; Manoukian, S; Peissel, B; Barile, M; Bonanni, B; Viel, A; Pensotti, V; Tommasi, S; Peterlongo, P; Weitzel, JN; Osorio, A; Benitez, J; McGuffog, L; Healey, S; Gerdes, A-M; Ejlertsen, B; Hansen, TVO; Steele, L; Ding, YC; Tung, N; Janavicius, R; Goldgar, DE; Buys, SS; Daly, MB; Bane, A; Terry, MB; John, EM; Southey, M; Easton, DF; Chenevix-Trench, G; Antoniou, AC; Ottini, L (2016-02-09)
      Background BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 ...
    • Malignant Peripheral Nerve Sheath Tumor With Divergent Glandular Differentiation. 

      Miki, Y; Thway, K (2017-06)
      Malignant peripheral nerve sheath tumors (MPNST) are soft tissue neoplasms with evidence of nerve sheath differentiation. They usually arise from peripheral nerves or from preexisting benign nerve sheath neoplasms, often ...
    • MALT lymphoma arising on a background of reactive pulmonary lymphoid hyperplasia in a patient with systemic lupus erythematosus 

      Laggner, U; Khiroya, R; Wotherspoon, AC; Desai, SR; Nicholson, AG (Wiley, 2018-03)
    • Mammographic density and ageing: A collaborative pooled analysis of cross-sectional data from 22 countries worldwide. 

      Burton, A; Maskarinec, G; Perez-Gomez, B; Vachon, C; Miao, H; Lajous, M; López-Ridaura, R; Rice, M; Pereira, A; Garmendia, ML; Tamimi, RM; Bertrand, K; Kwong, A; Ursin, G; Lee, E; Qureshi, SA; Ma, H; Vinnicombe, S; Moss, S; Allen, S; Ndumia, R; Vinayak, S; Teo, S-H; Mariapun, S; Fadzli, F; Peplonska, B; Bukowska, A; Nagata, C; Stone, J; Hopper, J; Giles, G; Ozmen, V; Aribal, ME; Schüz, J; Van Gils, CH; Wanders, JOP; Sirous, R; Sirous, M; Hipwell, J; Kim, J; Lee, JW; Dickens, C; Hartman, M; Chia, K-S; Scott, C; Chiarelli, AM; Linton, L; Pollan, M; Flugelman, AA; Salem, D; Kamal, R; Boyd, N; Dos-Santos-Silva, I; McCormack, V (2017-06-30)
      Background Mammographic density (MD) is one of the strongest breast cancer risk factors. Its age-related characteristics have been studied in women in western countries, but whether these associations apply to women worldwide ...
    • Management of breast cancer--part I. 

      Turner, NC; Jones, AL (2008-01)
    • Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. 

      Califano, R; Greystoke, A; Lal, R; Thompson, J; Popat, S (2017-09)
      Anaplastic lymphoma kinase rearrangement (ALK+) occurs in approximately 2-7% of patients with non-small cell lung cancer (NSCLC), contributing to a considerable number of patients with ALK+ NSCLC worldwide. Ceritinib is a ...
    • The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. 

      Desmoid Tumor Working Group (2020-03)
      Desmoid tumor (DT; other synonymously used terms: Desmoid-type fibromatosis, aggressive fibromatosis) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterised by a variable and often unpredictable ...
    • Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. 

      Warde, P; Huddart, R; Bolton, D; Heidenreich, A; Gilligan, T; Fossa, S (2011-10)
      The treatment of patients with Stage I-II seminoma has changed considerably in the past decade, and in November 2009, an International Consensus meeting was held under the sponsorship of the Union for International Cancer ...
    • Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation. 

      Brand, D; Parker, C (2018-04)
      In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay ...
    • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 

      Gillessen, S; Omlin, A; Attard, G; de Bono, JS; Efstathiou, E; Fizazi, K; Halabi, S; Nelson, PS; Sartor, O; Smith, MR; Soule, HR; Akaza, H; Beer, TM; Beltran, H; Chinnaiyan, AM; Daugaard, G; Davis, ID; De Santis, M; Drake, CG; Eeles, RA; Fanti, S; Gleave, ME; Heidenreich, A; Hussain, M; James, ND; Lecouvet, FE; Logothetis, CJ; Mastris, K; Nilsson, S; Oh, WK; Olmos, D; Padhani, AR; Parker, C; Rubin, MA; Schalken, JA; Scher, HI; Sella, A; Shore, ND; Small, EJ; Sternberg, CN; Suzuki, H; Sweeney, CJ; Tannock, IF; Tombal, B (2019-12)
    • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 

      Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Bossi, A; Briganti, A; Bristow, RG; Chi, KN; Clarke, N; Davis, ID; de Bono, J; Drake, CG; Duran, I; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, FY; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Heinrich, D; Higano, CTS; Hofman, MS; Hussain, M; James, N; Kanesvaran, R; Kantoff, P; Khauli, RB; Leibowitz, R; Logothetis, C; Maluf, F; Millman, R; Morgans, AK; Morris, MJ; Mottet, N; Mrabti, H; Murphy, DG; Murthy, V; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Parker, C; Poon, DMC; Pritchard, CC; Reiter, RE; Roach, M; Rubin, M; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Shore, N; Small, E; Smith, M; Soule, H; Sternberg, CN; Steuber, T; Suzuki, H; Sweeney, C; Sydes, MR; Taplin, M-E; Tombal, B; Türkeri, L; van Oort, I; Zapatero, A; Omlin, A (2020-04)
      Background Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ...
    • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. 

      Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bossi, A; Bristow, R; Carver, B; Castellano, D; Chung, BH; Clarke, N; Daugaard, G; Davis, ID; de Bono, J; Borges Dos Reis, R; Drake, CG; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, F; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Higano, CS; James, N; Kantoff, P; Kellokumpu-Lehtinen, P-L; Khauli, RB; Kramer, G; Logothetis, C; Maluf, F; Morgans, AK; Morris, MJ; Mottet, N; Murthy, V; Oh, W; Ost, P; Padhani, AR; Parker, C; Pritchard, CC; Roach, M; Rubin, MA; Ryan, C; Saad, F; Sartor, O; Scher, H; Sella, A; Shore, N; Smith, M; Soule, H; Sternberg, CN; Suzuki, H; Sweeney, C; Sydes, MR; Tannock, I; Tombal, B; Valdagni, R; Wiegel, T; Omlin, A (2018-02)
      Background In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. ...
    • Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. 

      Terpos, E; Mikhael, J; Hajek, R; Chari, A; Zweegman, S; Lee, HC; Mateos, M-V; Larocca, A; Ramasamy, K; Kaiser, M; Cook, G; Weisel, KC; Costello, CL; Elliott, J; Palumbo, A; Usmani, SZ (2021-02-18)
      Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including ...